Background-Cardiac interstitial fibrosis is a major cause of the deteriorated performance of the heart in patients with chronic myocardial infarction. MicroRNAs (miRs) have recently been proven to be a novel class of regulators of cardiovascular diseases, including those associated with cardiac fibrosis. This study aimed to explore the role of miR-101 in cardiac fibrosis and the underlying mechanisms. Methods and Results-Four weeks after coronary artery ligation of rats, the expression of miR-101a and miR-101b
A cute myocardial infarction (MI) resulting from coronary artery occlusion is one of the leading causes of sudden death in the world. Although a large portion of patients survive the acute phase of MI with intense therapy, in the long run, it may gradually develop into chronic heart failure as a consequence of postinfarct cardiac remodeling. Interstitial fibrosis, occurring in both infarcted and noninfarcted myocardium, represents a characteristic pathological alteration of postinfarct remodeling and is regarded as a major determinant of the progressive deterioration of ventricular function and reduced ventricular compliance after MI. [1] [2] [3] Fibrosis is characterized by the excess deposition of extracellular matrix (ECM) proteins, eg, collagen I, collagen III, fibronectins, elastin, and fibrins. Cardiac fibroblasts (CFs), accounting for 60% to 70% of the cells in the human heart, are the main source of ECM production. 4 During MI, CFs are activated and produce excess amounts of ECM, leading to interstitial fibrosis and the untoward outcome of MI patients. 5 Therefore, great efforts have been devoted to this disease with the goal of elucidating the molecular mechanisms and developing novel antifibrotic strategies to improve its therapy.
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MicroRNAs (miRNAs) are endogenous small noncoding RNAs that anneal inexactly to complementary sequences in the 3Ј-untranslated regions of target mRNAs of protein-coding genes to regulate protein synthesis. Growing evidence shows that miRNAs play a critical role in the pathogenesis of cardiovascular diseases, including arrhythmia, 6 cardiac hypertrophy, [7] [8] [9] [10] heart failure, 11 and cardiac injury. 12, 13 Notably, the dysregulation of several miRNAs has been linked to the development and progression of cardiac fibrosis via regulation of various fibrosisrelated proteins. 14 -19 Upregulation of miRNA (miR)-21 provoked the development of fibrosis, 16, 19 whereas in vitro forced overexpression of miR-29, 17 miR-133, 14, 15, 18 miR-30c, 14 or miR-590 15 suppressed fibrotic responses of CFs. However, concerning the large number of miRNAs with 1921 sequences in humans (http://www.mirbase.org/), the involvement of miRNAs in cardiac fibrosis is far from fully elucidated.
In this study, we report that miR-101a, a frequently downregulated miRNA in hypertrophic and postinfarct hearts, is able to inhibit the proliferation of rat CFs. Forced overexpression of miR-101a carried by adenovirus in vivo attenuated cardiac interstitial fibrosis and improved left ventricular compliance of rats subjected to coronary artery ligation. This study indicated that manipulating the expression of miR-101a represents a promising therapeutic strategy for cardiac fibrosis.
Methods Animals
Healthy male Sprague-Dawley rats (weight, 200 -250 g) and C57BL/6 mice used in the present study were kept under standard animal room conditions (temperature, 21Ϯ1°C; humidity, 55%-60%) with food and water ad libitum for 1 week before the experiments. All experimental procedures were done in accordance with the Institutional Animal Care and Use Committee of the Harbin Medical University, PR China.
MI Models
Animals were anesthetized with ketamine-xylazine. Left descending coronary artery ligation was performed to induce cardiac infarction. For details, see the online-only Data Supplement.
Construction of Adenovirus Carrying premiR-101a
The procedures were similar to those in the study reported by van Rooij et al 11 and our previous study. 20 For details, see the online-only Data Supplement.
In Vivo Adenovirus Infection
Three days after surgery, rats were anesthetized and ventilated. The chest was reopened via the fourth intercostal space. The ascending aortic artery and main pulmonary artery were clamped; then, adenovirus carrying premiR-101a (Adv-miR-101a) or empty adenovirus (Adv-control; 1ϫ10 9 plaque-forming units at the volume of 200 L) was injected into the left ventricular cavity through the tip of the heart with a 30-gauge syringe. The arteries were occluded for 10 seconds after adenovirus injection. Rats in the sham and MI groups underwent the same procedures and received 200 L saline.
Echocardiographic and Hemodynamic Measurements
Four weeks after the injection of adenovirus, we used transthoracic echocardiography with an ultrasound machine (Vivid 7 GE Medical) equipped with a 10-MHz phased-array transducer to test left ventricular function. A pressure-volume control unit (Scisense Inc, Canada) was used to measure hemodynamic indexes. For details, see the online-only Data Supplement.
Histological Analysis of Collagen Content and Infarct Size
The left ventricle was fixed in 4% paraformaldehyde, embedded with paraffin, and cut cross-sectionally into 5-m-thick sections along the center of the fibrotic scar. Masson trichrome staining was used to evaluate collagen deposition. Sections were imaged at ϫ200 magnification by bright-field microscopy (IX71 Olympus, Japan). The quantity of cardiac fibrosis was assessed by calculating collagen volume fraction. Collagen volume fraction was determined as the ratio of collagen surface area stained blue to the myocardial surface area. Infarct size was assessed by examining images obtained at low magnification and calculated as the ratio of scar average circumferences to left ventricular average inner circumferences. All quantitative evaluations were carried out by ImagePro Plus software (version 6.0, Media Cybernetics).
CF Isolation and Culture
See the online-only Data Supplement.
Measurement of Collagen Production
Hydroxyproline content in cardiac tissues was measured with a hydroxyproline assay kit according to the manufacturer's instructions.
Terminal Deoxynucleotidyl Transferase dUTP Nick-End Labeling Staining
Apoptosis of cardiac myocytes was determined by staining cryosections of rat hearts with the In situ Cell Death Detection Kit (terminal deoxynucleotidyl transferase dUTP nick-end labeling [TUNEL] fluorescence FITC kit, Roche, Indianapolis, IN) according to the manufacturer's instructions. After TUNEL staining, the heart sections were immersed into a DAPI (Sigma-Aldrich) solution to stain nuclei. Fluorescence staining was viewed by laser scanning confocal microscopy (FV300, Olympus, Japan). TUNEL-positive cells were counted in 3 fields (ϫ200 magnification) of each cryosection.
Proliferation Assay of CFs
Both cell counting and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell vitality assay were used to measure CF proliferation. CFs were seeded onto 96-well tissue culture plates (5ϫ10 3 cells per well) in Dulbecco modified Eagle medium with 10% FBS. After culturing in serum-free Dulbecco modified Eagle medium for 24 hours, angiotensin II (AngII; 1ϫ10 Ϫ7 mol/L; Sigma), alone or in combination with miR-101a/b, miR-101a/bϩAMO-101a/b, or negative control, was added to the medium. After 48 hours of incubation, the CFs were trypsinized and counted with a hemocytometer. Then, the CFs were treated with MTT (5 mg/mL) for 4 hours at 37°C. The amount of metabolized MTT was determined with a microplate reader. 
Western Blot
Total protein samples were extracted from the cultured CFs and the left ventricular peri-infarct region of rats for protein immunoblotting using essentially the same procedures described in detail elsewhere. 21 For details, see the online-only Data Supplement.
Quantitative Reverse Transcription-Polymerase Chain Reaction
Total RNA samples from cultured fibroblasts and cardiac tissues were isolated by use of the Trizol reagent (Invitrogen) according to manufacturer's protocols. The RNA levels of c-fos, transforming growth factor-␤1 (TGF-␤1), collagen I, collagen III, and fibronectin-1 were determined with the SYBR Green I incorporation method on an ABI 7500 fast real-time polymerase chain reaction system (Applied Biosystems, Foster City, CA) with ␤-actin as an internal control. The levels of miR-101a and miR-101b were tested with the TaqMan MicroRNA Assay Kit (Applied Biosystems) with U6 as an internal control. For details, see the online-only Data Supplement.
Synthesis of miR-101a/b and Anti-miR-101a/b Antisense Inhibitors
miR-101a, miR-101b, and their antisense oligonucleotides, AMO101a and AMO-101b, were synthesized by GenePharma (Shanghai GenePharma Co, Ltd). A scrambled RNA was used as negative control. For details, see the online-only Data Supplement.
Construction of the Plasmid Expressing siRNA for Rat FOS
The siRNA for Rattus norvegicus FBJ osteosarcoma oncogene (FOS; NM_022197) was constructed by use of the plasmid pGCsilencer- 
Construction of Rat FOS Overexpression Vector
The protein encoding sequence of the FOS mRNA (NM_022197) was amplified with the following primer pair: forward, 5Ј-CCGCTCGAGA TGATGTTCTCGGGTTTCAACGC-3Ј; reverse, 5Ј-GGGGTACCGTC AGGGCTAGCAGTGTGGGCGAG-3Ј. The obtained FOS mRNA sequence was then cloned into pEGFP-N1 vector (pEGFP-N1-Fos-GFP) containing a cytomegalovirus promoter. The empty pEGFP-N1 plasmid was used as a negative control.
Luciferase Assays
Data Analysis
All data were analyzed statistically by 1-way ANOVA followed by the Tukey multiple-comparisons test (GraphPad Prism version 5.0). Differences were considered statistically significant when PϽ0.05.
Results

Downregulation of miR-101a and miR-101b in Infarcted Heart and Serum-Treated Rat CFs
The expression of miR-101a and miR-101b in postinfarct cardiac tissues and cultured CFs was first detected under the conditions with significant CF proliferation. At 3, 7, 14, and 28 days after coronary artery ligation, the expression of both miR-101a and miR-101b in the peri-infarct area of rat hearts was decreased compared with sham-operated animals ( Figure 1A ). In serum-treated cultured neonatal rat CFs, the expression of miR-101a and miR-101b was lower than in untreated control cells ( Figure 1B) . Treatment with 100 nmol/L AngII on CFs also suppressed the expression of miR-101a/b ( Figure 1C ). In addition, the level of miR-101a/b was Ϸ2-fold higher in CFs than in cardiac myocytes ( Figure 1D ). These results indicated the possible involvement of miR-101 in CF proliferation.
miR-101a/b Inhibits the Proliferation of CFs
The effect of miR-101a on neonatal CFs proliferation was evaluated by cell counting and MTT assay. Treatment with 100 nmol/L AngII on CFs led to a significant increase in CF proliferation. Overexpression of miR-101a (50 nmol/L) inhibited AngII-induced proliferation of CFs, whereas cotransfection with AMO-101a (100 nmol/L), the specific inhibitor of miR101a, abrogated the effects of miR-101a (Figure 2A 
Involvement of c-Fos in miR-101a-Mediated Suppression of CF Proliferation
FOS was reported to regulate expression of TGF␤1 and proliferation of CFs. Our computational analysis predicted that miR-101 has the potential to repress c-Fos: the 3Ј-untranslated region of FOS mRNA contains 1 binding site for miR-101 among humans, rats, and mice ( Figure III in the online-only Data Supplement). Previous study has experimentally identified human FOS mRNA as a target of miR-101 by luciferase assay. In this study, we first confirmed the regulation of rat and mouse FOS by miR-101a by luciferase assay ( Figure 3A and 3B) . We found that miR-101a significantly inhibited luciferase activity of the luciferase vectors containing the 3Ј-untranslated region of FOS mRNA, which was rescued by coapplication of AMO-101a to knock down miR-101. The specificity of miR-101a action was indicated by the absence of changes with the negative control ( Figure  3A and 3B) . We then tested the influence of miR-101a on the expression of c-Fos and its downstream protein TGF␤1, a well-established profibrotic cytokine, in CFs. Treatment of CFs with AngII (100 nmol/L) significantly increased the expression of c-Fos and TGF␤1 in both protein and mRNA levels ( Figure 3C-3F) . Overexpression of miR-101a inhibited AngII-induced expression of c-Fos and TGF␤1. The action of miR-101a was counteracted by cotransfection of AMO-101a, indicating the specificity of miR-101a action (Figure 3C-3F) .
To further confirm the role of c-Fos in the antiproliferative action of miR-101a in CFs, we performed gain-and loss-offunction studies on the expression of c-Fos using plasmid overexpression and siRNA techniques. Transfection of the c-Fos-expressing plasmid led to a significant increase in the expression of c-Fos protein and mRNA ( Figure 4A and 4B) . Cotransfection of miR-101a failed to inhibit c-Fos expression because the c-Fos-expressing plasmid did not contain the 3Ј-untranslated region of c-Fos ( Figure 4A and 4B) . Moreover, forced c-Fos expression upregulated the protein and mRNA expression of TGF␤1, whereas cotransfection with miR-101a did not produce further effects on TGF␤1 expression ( Figure 4C  and 4D) . Concomitantly, the production of collagen I and III was enhanced by c-Fos overexpression, and coapplication of miR101a did not affect the expression of collagen I and III (Figure Figure 5A and 5B). When c-Fos was suppressed by its siRNA, the expression of TGF␤1, collagen I, and collagen III was also inhibited, which was not further decreased by application of miR-101a ( Figure 5C-5F ). These data suggest that c-Fos and its downstream protein TGF␤1 play an important role in miR101a-mediated suppression of CF proliferation.
Overexpression of miR-101a Improves Cardiac Function of Infarcted Heart in Rats
We then investigated whether the beneficial effects exist in in vivo conditions. Three days after coronary artery ligation, adenovirus carrying the precursor of miR-101a was administered, which caused a continuous elevation of miR-101a until 4 weeks ( Figure IV in the online-only Data Supplement). Infarct size was similar among groups (Table 1) . Body weight ratio, ratio of left ventricle to body weight, and ratio of heart weight to body weight were not significantly different among groups (Table 1) .
Cardiac function was examined using echocardiography and hemodynamic measurements 4 weeks after adv-miR-101a infection. Echocardiography examination showed that ejection fraction and fractional shortening were significantly decreased in MI hearts, indicating impaired cardiac function (Table 2) . Overexpression of miR-101a attenuated the deterioration of left ventricular performance, as indicated by the increased ejection fraction and fractional shortening, and adenovirus carrying empty vector produced no effects (Table 2) . Four weeks after adv-miR-101a infection, the hemodynamic indexes of rats were measured before scarification. Heart rate among groups showed no differences ( Figure 6A) . In MI rats, mean arterial pressure and left ventricular developed pressure tended to decrease ( Figure 6B and 6C ) and left ventricular end-diastolic pressure tended to increase ( Figure 6D ) but did not reach statistical significance. However, compared with control rats, MI rats had significantly decreased dP/dtmax and ϪdP/dtmax, the compliance of the heart, indicating that the hearts of MI rats had become stiff ( Figure 6E and 6F) . Overexpression of miR101a rescued the decreased dP/dtmax and ϪdP/dtmax in MI rats, whereas the empty vector produced no effects ( Figure 6E and 6F). Additionally, Adv-miR-101a showed no influence on the hemodynamic indexes of sham rats (Figure 6 ), although collagen content was inhibited (Figure V in the online-only Data Supplement).
Overexpression of miR-101a Inhibits Interstitial Fibrosis of Infarcted Heart
Interstitial fibrosis is a major factor leading to increased myocardial stiffness and depressed cardiac compliance after MI. ECM deposition in the peri-infarct region was first assessed with Masson trichrome staining of cardiac tissue sections. The interstitial fibrotic area of MI rats significantly increased compared with sham controls. Transfection of miR-101a significantly alleviated ECM deposition, whereas the control vector for miR-101a produced no effects ( Figure 7A and 7B) . Moreover, mitigation of postinfarct ECM deposition by miR-101a was also confirmed by decreased collagen I, collagen III, and MMP-2/9 levels in peri-infarct myocardium ( Figure 7C-7F) . Additionally, miR-101a overexpression reduced apoptosis of cardiac myocytes in the peri-infarct area of MI hearts ( Figure 7G) .
The expression of c-Fos and TGF␤1 in the peri-infarct area of infarcted hearts was also evaluated 4 weeks after adv-miR-101a infection. As shown in Figure 8 , both the protein and mRNA levels of c-Fos and TGF␤1 were augmented in MI rats, and overexpression of miR-101a prevented this upregulation ( Figure  8 ), but the adenovirus carrying empty vector failed to do so.
Knockdown of miR-101a Fails to Further Aggravate Cardiac Dysfunction in MI
We also tested whether knockdown of miR-101a with locked nucleic acid-modified oligonucleotide against miR-101a (LNA-101a) could exacerbate cardiac dysfunction after MI. We found that LNA-101a did not further aggravate cardiac dysfunction ( Figure VI in the online-only Data Supplement) or increase matrix dysregulation ( Figure VII in the onlineonly Data Supplement). Body weight, left ventricle weightto-body weight ratio, and heart weight-to-body weight ratio were not significantly changed among groups (Table I in 
Discussion
In this study, we found that downregulation of miR-101a after cardiac infarction inhibited proliferation of CFs and production of collagen. In an in vivo study, we found that miR-101a suppressed cardiac fibrosis in the heart subjected to coronary artery ligation and improved the impaired cardiac function of MI hearts. Moreover, our data strongly suggest that suppression of c-Fos and its downstream protein TGF␤1 mediates the antifibrotic action of miR-101. Tissue specificity is one of the properties of miRNA expression that determine the specific contribution of certain miRNAs in the biological and pathological processes of an organ. 22 The antifibrotic miRNA, miR-30c, is more abundant in CFs than cardiac myocytes. 14 The levels of the profibrotic miRNA, miR-21, are increased selectively in fibroblasts of the failing heart. 19 We found that miR-101a and miR-101b are more enriched in CFs than cardiac myocytes. Deregulation of miRNAs is a common phenomenon that occurs in various diseases. 23 The aberrantly expressed miRNAs often participate in the pathogenesis of a certain disease. 11, 17, 22 The expression of miR-101 was consistently reported to be reduced in the cardiac tissue of heart diseases, including aortic stenosis, 24 dilated cardiac myopathy, 24 and ischemic heart disease. 17 In a previous study, we found that miR-101 was decreased by 50% in the atrium of a canine model of atrial fibrillation induced by atrial tachypacing. 20 In this model, interstitial fibrosis is a major structural alteration. 25, 26 In this study, we consistently found that the expression of both miR-101a and miR-101b was downregulated in the infarcted hearts of rats and the proliferating CFs treated with serum or AngII. These results imply the possible regulation of CFs by miR-101. This notion was verified by the fact that overexpression of miR-101a/b suppressed proliferation of CFs and collagen production in CFs, indicating that, in addition to the established miRNAs (miR-21, -133, -590, -30c), 14 -19 miR-101 is another fibrosis-related miRNA.
The molecular mechanisms underlying the regulation of fibrosis by miRNAs have often been attributed to the alteration of key signaling pathways in the pathological process of fibrotic growth. miR-21 augments extracellular signal-regulated kinase-mitogen-activated protein kinase activity through inhibition of sprouty homolog 1 and thus regulates fibroblast survival and growth factor secretion. 16 miR-21 was also reported to control the expression of MMP-2 via targeting phosphatase and tensin homolog. 19 miR-133 and miR-30 control the extent of interstitial fibrosis by directly downregulating connective tissue growth factor, a powerful inducer of ECM synthesis. 14 We have previously demonstrated that miR-133 and miR-590 alleviated collagen production in nicotine-induced atrial fibrosis through suppressing TGF␤1 and TGF␤ receptor type II. 15 In this study, we confirmed the important role of c-Fos in mediating miR-101-induced antifibrotic action. c-Fos is a protein encoded by the FOS gene 27 that dimerizes with c-Jun to form the transcriptional factor activator protein-1. 28 Upregulation of c-Fos by tumor necrosis factor-␣ has been shown to increase the transcription of TGF␤1, a key cytokine that promotes fibrosis, in lung fibroblasts. 29 Globular adiponectin enhanced c-Fos/c-Jun gene expression and activator protein-1 activation and thus the stimulation of CFs. 30 However, there is no direct evidence for the role of the signaling pathway of c-Fos/TGF␤1 in CFs. In this study, we used both gain-and loss-of-function techniques on c-Fos expression to explore the regulatory effect of c-Fos on TGF␤1 expression and its role in mediating the antifibrotic action of miR-101. We found that when c-Fos is knocked down by siRNA technique, TGF␤1 expression was significantly suppressed in CFs. On the contrary, forced overexpression of c-Fos enhanced the expression of TGF␤1, together with the production of collagen proteins. These results confirmed that the c-Fos/ TGF␤1 pathway plays a critical role in the proliferation of CFs. Furthermore, when c-Fos expression was directly manipulated, being either silenced by siRNA or enhanced by overexpression, miR-101 lost the ability to alter fibrosis, indicating that c-Fos/ TGF␤1 is a downstream component in the miR-101 signaling pathway. In addition, in silico prediction with Targetscan shows that FOS is a target of miR-101, which is conserved among species. A previous study by Li et al 31 confirmed the regulation of human FOS by miR-101 using both the luciferase reporting method and protein expression technique. We also experimentally confirmed that FOS is the direct target of miR-101 in both rats and mice. One miRNA can regulate hundreds of mRNAs. 32, 33 In addition to FOS being a target for miR-101 as established in the present study, some other targets have been previously validated, including enhancer of Zeste homolog 2, 34 myeloid cell leukemia sequence 1, 35 membrane-associated guanylate kinase, 36 and cyclooxygenase-2. 37 Even though our data strongly support the involvement of FOS in miR-101-mediated antifibrotic effects, we cannot rule out the participation of other genes in this process. The sequence of miR-101 is identical among various species, including humans and rats, implying that the beneficial effects of miR-101a on cardiac fibrosis observed in this study may be extrapolated to human beings. Additionally, c-Fos was demonstrated to upregulate the expression of miR-21, 38 a well-defined profibrotic miRNA. Thus, miR-21 may also be involved in the antifibrotic action of miR-101.
Our results show that MI caused cardiomyocyte apoptosis in our study and that miR-101 overexpression reduced apoptotic cell death. However, we observed no effects of miR-101 overexpression or knockdown on cell viability and apoptosis in cultured cardiac myocytes ( Figure VIII in the online-only Data Supplement). These data indicate that miR-101 has no direct effects on apoptosis, and the observed decrease in cardiomyocyte apoptosis in infarcted heart after miR-101 treatment is more likely a consequence of the improved cardiac function by miR-101. A previous study by Li et al 31 showed that miR-101 promotes apoptosis in hepatoma cells. The most reasonable explanation for the discrepancy between our study and the study reported by Li et al is the different cells used in these 2 studies; different cells may well have different survival and apoptotic signaling pathways or mediators as targets for miR-101a. In the study by Li et al, cancer cells were used; in the present study, CFs and cardiomyocytes were studied.
In this study, we identified a novel antifibrotic miRNA, miR-101a. In vivo overexpression of miR-101a carried by adenovirus is able to alleviate the fibrotic growth of the infarcted heart in rats, and the underlying mechanism involves an inhibition of the c-Fos/TGF␤1 pathway. This study indicates that exogenous application of miR-101 may be a promising intervention in the management of cardiac fibrosis and the associated pathological processes. 
CLINICAL PERSPECTIVE
Myocardial infarction caused by coronary artery occlusion is one of the leading causes of sudden death in the world. Interstitial fibrosis, occurring in both infarcted and noninfarcted myocardium, represents a characteristic pathological alteration of postinfarct remodeling and is regarded as a major determinant of the progressive deterioration of ventricular function and reduced ventricular compliance after myocardial infarction. Fibrosis is characterized by excessive deposition of extracellular matrix proteins. Cardiac fibroblasts, accounting for 60% to 70% of the cells in the human heart, are the main source of extracellular matrix protein production. During myocardial infarction, cardiac fibroblasts are activated and produce excessive amount of extracellular matrix proteins, leading to interstitial fibrosis. Tremendous efforts have been devoted to this pathological process to elucidate the molecular mechanisms and to develop novel antifibrotic strategies. MicroRNAs (miRs), endogenous small noncoding RNAs that regulate the expression of genes, have recently been proven to be a novel class of regulators of cardiovascular diseases, including those associated with cardiac fibrosis. In this study, we discovered that downregulation of an miR called miR-101 contributes significantly to cardiac fibrosis in myocardial infarction hearts; forced expression of miR-101 suppresses cardiac fibrosis and improves the impaired cardiac function in postinfarct rats. Our findings reveal the role of miRNA in controlling cardiac fibrosis in myocardial infarction hearts and indicate that miR-101 is a viable therapeutic strategy for cardiac disease associated with fibrosis. It is speculated that administration of miR-101 mimetics should produce antifibrotic actions, thereby retarding structural remodeling and minimizing functional deterioration of the heart under a variety of pathological settings.
